CN102872139A - Application of Houttuynoid C in drug for treating tongue cancer - Google Patents
Application of Houttuynoid C in drug for treating tongue cancer Download PDFInfo
- Publication number
- CN102872139A CN102872139A CN2012104195781A CN201210419578A CN102872139A CN 102872139 A CN102872139 A CN 102872139A CN 2012104195781 A CN2012104195781 A CN 2012104195781A CN 201210419578 A CN201210419578 A CN 201210419578A CN 102872139 A CN102872139 A CN 102872139A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- drug
- tongue cancer
- application
- tongue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCCCCCCCCc(c1c(cc2)C(*(c3cc(O)cc(O)c3C3=*)=*=C)=C3OC(C3O)O[C@](C*)C(*)C3O)c[o]c1c2O Chemical compound CCCCCCCCCCc(c1c(cc2)C(*(c3cc(O)cc(O)c3C3=*)=*=C)=C3OC(C3O)O[C@](C*)C(*)C3O)c[o]c1c2O 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Houttuynoid C in a drug for treating tongue cancer, belonging to the technical field of the new use of the drug. Houttuynoid C is found to have obvious inhibition effect on the growth of human tongue cancer cell lines Tca8113 and T6 through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid C can be used for preparing the anti-tongue cancer drug and has excellent prospects in development and application. The use of Houttuynoid C in preparing the drug for treating the tongue cancer involved in the invention is disclosed for the first time; the framework type of Houttuynoid C is a brand new framework type; and Houttuynoid C has an unexpectedly high inhibition activity for the tongue cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in the anti-carcinoma of tongue medicine of preparation.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid C that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid C that the present invention relates in preparation treatment carcinoma of tongue medicine, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of tongue obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid C in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in the anti-carcinoma of tongue medicine of preparation, and the structural formula of Houttuynoid C is shown in formula I:
Formula I
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid C also has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6, suppresses the IC of this 2 strain Growth of Cells
50Value is respectively 0.81 ± 0.11 μ M and 2.39 ± 0.26 μ M.Therefore, Houttuynoid C can for the preparation of anti-carcinoma of tongue medicine, have good development prospect.
The purposes of the Houttuynoid C that the present invention relates in preparation treatment carcinoma of tongue medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for Human Tongue Carcinoma Lines is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously carcinoma of tongue obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Houttuynoid C to the growth inhibited effect of people's Human Tongue Carcinoma Lines strain
1. method: the cell that is in the growth logarithmic (log) phase: people's Human Tongue Carcinoma Lines strain Tca8113 and T6(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.This chemical compound suppresses the IC of people Human Tongue Carcinoma Lines strain Tca8113 and T6 growth
50Value is respectively: 0.81 ± 0.11 μ M and 2.39 ± 0.26 μ M.
Shown by above-described embodiment, Houttuynoid C of the present invention has good inhibitory action to the growth of people's Human Tongue Carcinoma Lines strain Tca8113 and T6.Prove thus, it is active that Houttuynoid C of the present invention has anti-carcinoma of tongue, can be for the preparation of anti-carcinoma of tongue medicine.
Claims (1)
1.Houttuynoid the application of C in treatment carcinoma of tongue medicine, described compound H outtuynoid C-structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419578 CN102872139B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating tongue cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419578 CN102872139B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating tongue cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872139A true CN102872139A (en) | 2013-01-16 |
| CN102872139B CN102872139B (en) | 2013-12-18 |
Family
ID=47473810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419578 Expired - Fee Related CN102872139B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating tongue cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872139B (en) |
-
2012
- 2012-10-27 CN CN 201210419578 patent/CN102872139B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 20120313: "Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata", 《ORGANIC LETTERS》 * |
| 郭艳华等: "鱼腥草总黄酮的提取纯化及黄酮类型的初步鉴定", 《食品科学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872139B (en) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872129B (en) | Application of Houttuynoid E in drug for treating endometrial cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872101B (en) | Application of Houttuynoid C in medicine for treating ileocecum cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861099A (en) | Application of Houttuynoid D in medicine for treating endometrial cancer | |
| CN102872125A (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872122A (en) | Application of Houttuynoid B in medicament for treating pancreatic cancer | |
| CN102861070A (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872138A (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872135A (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872103A (en) | Application of Houttuynoid E in medicine for treating nasopharyngeal carcinoma | |
| CN102872102A (en) | Application of Houttuynoid C in medicine for treating breast cancer | |
| CN102872093A (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872111A (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102872110A (en) | Application of Houttuynoid D in medicament for treating breast cancer | |
| CN102861080A (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872117A (en) | Application of Houttuynoid D in medicament for treating gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU KANGHENG CHEMICAL CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141128 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226500 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141128 Address after: 226500, Jiangsu, Rugao town (Rugao port area) 8 West Hong Kong Road (Fine Chemical Industry Park) Patentee after: Jiangsu Kangheng Chemical Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131218 Termination date: 20191027 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |